Preclinical validation of a novel metastasis-inhibiting Tie1 function-blocking antibody

ABSTRACT: The Angiopoietin (Ang)-Tie pathway has been intensely pursued as candidate second generation anti-angiogenic target. While much of the translational work has focused on the ligand Ang2, the clinical efficacy of Ang2-targeting drugs is limited and failed to improve patient survival. In turn, the orphan receptor Tie1 remains therapeutically unexplored, although its endothelial-specific genetic deletion has previously been shown to result in a strong reduction in metastatic growth. Here, we report a novel Tie1 function-blocking antibody (AB-Tie1-39), which suppressed postnatal retinal angiogenesis. During primary tumor growth, neoadjuvant administration of AB-Tie1-39 strongly impeded systemic metastasis. Furthermore, administration of AB-Tie1-39 in a perioperative therapeutic window led to a

SUBMITTER: Dr. Mahak Singhal 

PROVIDER: S-SCDT-EMM-2019-11164 | biostudies-other |

REPOSITORIES: biostudies-other